27 July 2006
8 June 2006
27 April 2006
14 March 2006
2 February 2006
Second quarter & half year results 2006
Presented by
David Brennan (Chief Executive Officer)
Jon Symonds (Chief Financial Officer)
8 June 2006
Business review 2006
Presenters biographies - (PDF 467 kb)
Part 1: Introduction, Pipeline overview & Cardiovascular
Introduction - David Brennan (PDF 54 kb)Pipeline overview - John Patterson (PDF 403 kb)Crestor - Elaine Campbell (PDF 1,5 mb)AZD6140, AGI-1067 - Howard Hutchinson (PDF 145 kb)Cardiovascular - Gunnar Olsson (PDF 236 kb)Part 2: Neuroscience and Respiratory & Inflammation
Part 3: Infection & Oncology
Infection - John Rex (PDF 174 kb)Zactima, AZD2171 - Alan Barge (PDF 632 kb)Oncology - Brent Vose (PDF 471 kb)Part 4: Business overview & conclusion
Business overview - Jon Symonds (PDF 131 kb)
27 April 2006
2006 Annual General Meeting
David Brennan (Chief Executive Officer) - (PDF 984 kb)
14 March 2006
Education seminar on Merck arrangements
Presentation with script - (PDF 711 kb)
2 February 2006
Fourth quarter and full year results 2005
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceStock symbol - AZN
On LSE, NYSE and OMX
Introduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
